FENNEC Aktie

 

RESEARCH TRIANGLE PARK, N.C., June 22, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on June 10, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 15,000 of the Company's common shares to one new non-executive employee of the Company with a grant date of June 22, 2026 under the Company's 2026 Equity Inducement Plan (the “Inducement Plan”). The ISOs were granted as inducements material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)....

RESEARCH TRIANGLE PARK, N.C., June 15, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on June 10, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 10,000 of the Company's common shares to one new non-executive employee of the Company with a grant date of June 15, 2026 under the Company's 2026 Equity Inducement Plan (the “Inducement Plan”). The ISOs were granted as inducements material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)....

RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 28, 2026 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held online on June 10, 2025....

Raykov, Rosty - Aufsichtsrat - Tag der Transaktion: 2026-06-01...

~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~...

RESEARCH TRIANGLE PARK, N.C., May 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on May 11, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of stock option awards (“Stock Options”) to purchase an aggregate of 50,000 of the Company's common shares to three new non-executive employees of the Company with a grant date of May 18, 2026 under the Company's 2026 Equity Inducement Plan (the “Inducement Plan”). The Stock Options consist of incentive stock options to purchase an aggregate of 49,141 shares and nonqualified stock options to purchase an aggregate of 859 shares. The Stock Options were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)....

Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

FENNEC PHARMACEUTICALS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE...

Rallis, Chris A. - Aufsichtsrat - Tag der Transaktion: 2026-05-11...

RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2026 financial results before the opening of the U.S. financial markets on Thursday, May 14, 2026. Management will host a conference call and webcast that day to discuss the Company's financial and business results....

Raykov, Rosty - Aufsichtsrat - Tag der Transaktion: 2026-05-01...

– Data from Four Studies Spotlight Rising Clinical Interest & Urgency to Address Cisplatin-Induced Hearing Loss and Its Lasting Impact on Patients –...

~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK® in AYA & Adult Patients with Solid Tumors Receiving Cisplatin ~...

Raykov, Rosty - Aufsichtsrat - Tag der Transaktion: 2026-04-01...

RESEARCH TRIANGLE PARK, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on March 17, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 377,500 of the Company's common shares to 24 new non-executive employees of the Company with a grant date of March 31, 2026 under the Company's 2026 Equity Inducement Plan (the “Inducement Plan”). The ISOs were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)....

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

~ Delivered Record Annual Revenue with Full-Year Net PEDMARK® Product Sales of $44.6 Million, Representing 50% Year-Over-Year Growth, and Q4 2025 Net Product Sales of $13.8 Million, Representing 75% Growth Over Q4 2024 Net Product Sales ~...

RESEARCH TRIANGLE PARK, N.C., March 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2025 financial results before the opening of the U.S. financial markets on Tuesday, March 24, 2026. Management will host a conference call and webcast that day to discuss the Company's financial and business results....